Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

Table 5

Ongoing treatment studies evaluating MoAbs in endometrial cancer patients.

Protocol number	Disease stage	Target therapy	Adjuvant treatment	Study phase	PI
NCT01010126	Endometrial cancer	Bevacizumab	Temsirolimus	Phase II	Charles Erlichman, MD
NCT00977574	Endometrial cancer	Bevacizumab	Temsirolimus Carboplatin ixabepilone Paclitaxel temsirolimus	Phase II	Carol Aghajanian, MD
NCT01005329	Endometrial cancer	Bevacizumab	Carboplatin Cisplatin	Phase II	Akila Viswanathan, MD
			Paclitaxel radiotherapy
NCT01367002	Uterine serous	Trastuzumab	Carboplatin Paclitaxel	Phase II	Alessandro D Santin, M.D.
NCT01256268	Endometrial Cancer	Ridaforolimus	Paclitaxel Carboplatin	Phase I	Robert Wenham, M.D.
NCR01244438	Endometrial Cancer with FGFR mutation	FP-1039	/	Phase II	Sarah Thayer
NCT01065246	Epithelial Carcinomas	Catumaxomab		Phase II	Jalid Sehouli, MD